Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis

• Published in: Annals of medicine and surgery 2024-07, Vol.86 (7), p.4130-4138
• Main Authors: Raja, Adarsh, Subhash Sagar, Raja, Saeed, Sadia, Zia Ul Haq, Amna, Khan, Owais, Dileep Bhimani, Parshant, Raja, Sandesh, Deepak, Fnu, Ahmed, Muhammad, Ashir Shafique, Muhammad, Saqlain Mustafa, Muhammad, Sohaib Asghar, Muhammad, Sharma, Varsha
• Format: Article
• Language: English
• Subjects: Reviews
• ISSN: 2049-0801; 2049-0801
• DOI: 10.1097/MS9.0000000000002195

Non-alcoholic fatty liver disease (NAFLD), spanning from non-alcoholic steatohepatitis (NASH) to liver fibrosis, poses a global health challenge amid rising obesity and metabolic syndrome rates. Effective pharmacological treatments for NASH and liver fibrosis are limited. This study systematically reviews and meta-analyzes the safety and efficacy of resmetirom, a selective thyroid hormone receptor-β agonist, in NASH and liver fibrosis treatment. By analyzing data from clinical trials, we aim to offer evidence-based recommendations for resmetirom's use in managing these conditions and identify avenues for future research. Electronic databases (PubMed, Scopus, Science Direct, Google Scholar, ClinicalTrials.gov, and Cochrane CENTRAL) were systematically searched, supplemented by manual screening of relevant sources. Only English-language randomized controlled trials were included. Data extraction, risk of bias assessment, pooled analyses, and meta-regression were performed. Three randomized controlled trials involving 2231 participants were analyzed. Resmetirom demonstrated significant reductions in hepatic fat fraction [standardized mean difference (SMD) -4.61, 95% CI -6.77 to -2.44, < 0.0001], NASH resolution without worsening fibrosis [risk ratio (RR) 2.51, 95% CI 1.74-3.64, = 0.00001), and liver fibrosis improvement (RR 2.31, 95% CI 1.20-4.44, = 0.01). Secondary outcomes showed significant improvements in lipid profiles, liver enzymes, and NASH biomarkers with resmetirom treatment. Meta-regression revealed associations between covariates and primary outcomes. Resmetirom exhibits promising efficacy in reducing hepatic fat, improving NASH resolution, and ameliorating liver fibrosis with a favorable safety profile. Further research is warranted to validate findings and optimize therapeutic strategies for NASH and liver fibrosis management.